Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner and 1 distinct art unit, showing a focused prosecution status for the university's current filings. This singular focus within 1 distinct art unit indicates that the university's current patenting efforts are concentrated in a specific area of biotechnology. For the legal team, this means that the prosecution strategy can be highly specialized to meet the requirements of this particular technical field. The existence of 1 pending office action allows for a dedicated focus on a single set of examiner requirements.
BICKHAM, DAWN MARIE is the busiest examiner for the portfolio, overseeing 1 pending office action. This single case represents the entirety of the university's current pending workload, as the busiest examiner pending count is 1. Prosecution efforts should be directed toward the specific requirements of this examiner within the Biotechnology & Pharmaceuticals field. Because there are no other pending office actions, the university's current success at the patent office depends on the resolution of this one matter. Practitioners should evaluate this examiner's past decisions to better understand the likely path forward for this specific application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BICKHAM, DAWN MARIE | 1 | 46.2% | +64.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629091 | A METHOD TO ASSIST IN THE EARLY DIAGNOSIS OF PANCREATIC ADENOCARCINOMA | BICKHAM, DAWN MARIE | 73d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629091 | A METHOD TO ASSIST IN THE EARLY DIAGNOSIS OF PANCREATIC ADENOCARCINOMA | BICKHAM, DAWN MARIE | 73d overdue |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17629091 | A METHOD TO ASSIST IN THE EARLY DIAGNOSIS OF PANCREATIC ADENOCARCINOMA | BICKHAM, DAWN MARIE | 1685 | §101§103 | Final Rejection | 73d overdue | Pending | Jan 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial